Sarda Proteins is significantly expanding its authorized capital and altering its business objectives. This comes alongside a major leadership reshuffle with the MD and three directors resigning, and new appointments made.
Sarda Proteins Ltd. Announces Major Capital Expansion and Leadership Overhaul
Sarda Proteins will increase authorized equity share capital from ₹13 crore to ₹100 crore and has appointed a new MD and CFO.
Reader Takeaway: Potential growth driven by capital expansion, but leadership turnover adds uncertainty.
What just happened
Sarda Proteins Ltd. has announced a significant increase in its authorized equity share capital, boosting it from ₹13 crore to ₹100 crore. This move, along with an alteration of the Object Clause in its Memorandum of Association, signals a strategic shift. Concurrently, the company has undergone a substantial leadership change.
Why this matters
This dual development of capital expansion and leadership transition is critical for investors. The capital increase and altered business objectives suggest preparations for future growth or diversification. However, the simultaneous resignation of the Managing Director and three directors, followed by new appointments, introduces a governance aspect that requires investor attention.
The backstory
Previously, Sarda Proteins had an authorized capital of ₹13 crore, comprising 1,30,00,000 shares with a face value of ₹10 each. The recent board decisions aim to increase this to ₹100 crore, representing 10,00,00,000 shares.
What changes now
Mr. Shirish Dhirajlal Savaliya has been appointed as the new Managing Director for a five-year term. Ms. Drashti Harshadbhai Delvadiya is the new Chief Financial Officer. The former CFO, Mr. Yagnik Arvindbhai Satasiya, is now an Additional Director and chairperson. These changes are effective July 4, 2026. The company is also seeking shareholder approval for these structural changes via an Extraordinary General Meeting (EGM).
Risks to watch
The simultaneous resignation of the MD and three directors raises concerns about governance volatility and potential disruption to strategic continuity. Investors will need to monitor the company's performance and strategic execution under the new leadership team.
Peer comparison
No direct peer comparison data was provided in the filing.
Context metrics (time-bound)
- Previous Authorized Capital: ₹13 crore
- New Authorized Capital: ₹100 crore
- Previous Equity Shares: 1,30,00,000
- New Equity Shares: 10,00,000
- Face Value per Share: ₹10
- Effective Date of Leadership Changes: July 4, 2026
What to track next
Investors should closely follow the upcoming EGM to understand the specific business objectives behind the altered Memorandum of Association. Monitoring the performance and strategic direction under the new MD and CFO will be crucial for assessing the company's future prospects.